Zydus Lifesciences has informed that the financial results of the company for Q3 2024-25 (October - December 2024) will be declared on February 5, 2025. Post results Q&A session through webinar has been scheduled on the same day, February 5, 2025, at 4:00 pm. Dr. Sharvil Patel, Managing Director, the company would be hosting the call. The details to join the call are provided in the attached file. Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the audio recording of the earnings call will be available on the Company’s website at https://www.zyduslife.com/investorzone. The transcript of the call will also be available subsequently at https://www.zyduslife.com/investorzone.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: